Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:


Discovery in cell signaling could help fight against melanoma

The human body does a great job of generating new cells to replace dead ones but it is not perfect. Cells need to communicate with or signal to each other to decide when to generate new cells. Communication or signaling errors in cells lead to uncontrolled cell growth and are the basis of many cancers.
At The University of Texas Health Science Center at Houston (UTHealth) Medical School, scientists have made a key discovery in cell signaling that is relevant to the fight against melanoma skin cancer and certain other fast-spreading tumors.

The scientists report that they have discovered why a class of drug called BRaf inhibitors that are widely used to treat melanomas do not always work and most importantly how these drugs may potentially accelerate cancer growth in certain patients. Melanoma, according to the American Cancer Society, accounts for almost 9,000 deaths each year. The scientistsf research was published online ahead of the June 5 print issue of Current Biology, which is published by Cell Press.

gThis information may aid the development of more effective anti-cancer drugs and better inform the choice of new combinations of drugs,h said John Hancock, M.B, B.Chir, Ph.D., the studyfs senior author, John S. Dunn Distinguished University Chair in Physiology and Medicine, chairman of the Department of Integrative Biology and Pharmacology and interim director of the Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases at the UTHealth Medical School.

Growth signals are transmitted from a cellfs surface to the nucleus by a chain of proteins that form a signaling pathway. The command for cells to divide to generate new cells is relayed by a chain of four proteins (Ras ¨ BRaf ¨ MEK ¨ ERK). All cells have this pathway and it does an effective job of generating new cells most of time.

Problems happen when a mutation occurs in one of the first two proteins in the chain - both of which lock the signaling pathway in the gonh position. The good news is that doctors have drugs that block signaling from the second protein known as BRaf. These are the BRaf inhibitors, which are successful at treating melanomas with mutant BRaf proteins.

The not-so-good news is that doctors cannot block the signal from the first protein called Ras. Researchers therefore studied in vivo what happens when BRaf inhibitors are applied to human cancer tissues with Ras mutations.

gSurprisingly recent studies found that BRaf inhibitors do not block signaling in melanoma cells with Ras mutations. In fact, the drugs actually enhance the abnormal signaling activity. Our work now describes the mechanism for this seemingly paradoxical enhanced signaling activity,h said Kwang-jin Cho, Ph.D., the studyfs lead author and research fellow at the UTHealth Medical School.

Most melanomas isolated from patients turn out to have either a BRaf or Ras mutation but rarely have both. Ras mutations cause an otherwise normal BRaf protein to stay switched on.

gOur study also emphasizes the importance of genetic testing of melanomas before using BRaf inhibitors. Our study may also help design a better drug,h Cho said.

The study, which is titled gRaf inhibitors target Ras spatiotemporal dynamics,h was supported by the Cancer Prevention & Research Institute of Texas.

Hancock and Chofs co-authors from the UTHealth Medical School are: Jin-Hee Park, senior research assistant; Sravanthi Chigurupati, senior research assistant; Dharini van der Hoeven, Ph.D., research fellow; and Sarah J. Plowman, Ph.D., assistant professor.

Other collaborators include: Rinshi S. Kasai, Ph.D., and Akihiro Kusumi, Ph.D., Kyoto University, Japan; and Sonja J. Heidorn, Ph.D., and Richard Marais, Ph.D., Institute for Cancer Research, London.
Rob Cahill
Media Hotline: 713-500-3030

Robert Cahill | EurekAlert!
Further information:

More articles from Life Sciences:

nachricht Novel mechanisms of action discovered for the skin cancer medication Imiquimod
21.10.2016 | Technische Universität München

nachricht Second research flight into zero gravity
21.10.2016 | Universität Zürich

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: New 3-D wiring technique brings scalable quantum computers closer to reality

Researchers from the Institute for Quantum Computing (IQC) at the University of Waterloo led the development of a new extensible wiring technique capable of controlling superconducting quantum bits, representing a significant step towards to the realization of a scalable quantum computer.

"The quantum socket is a wiring method that uses three-dimensional wires based on spring-loaded pins to address individual qubits," said Jeremy Béjanin, a PhD...

Im Focus: Scientists develop a semiconductor nanocomposite material that moves in response to light

In a paper in Scientific Reports, a research team at Worcester Polytechnic Institute describes a novel light-activated phenomenon that could become the basis for applications as diverse as microscopic robotic grippers and more efficient solar cells.

A research team at Worcester Polytechnic Institute (WPI) has developed a revolutionary, light-activated semiconductor nanocomposite material that can be used...

Im Focus: Diamonds aren't forever: Sandia, Harvard team create first quantum computer bridge

By forcefully embedding two silicon atoms in a diamond matrix, Sandia researchers have demonstrated for the first time on a single chip all the components needed to create a quantum bridge to link quantum computers together.

"People have already built small quantum computers," says Sandia researcher Ryan Camacho. "Maybe the first useful one won't be a single giant quantum computer...

Im Focus: New Products - Highlights of COMPAMED 2016

COMPAMED has become the leading international marketplace for suppliers of medical manufacturing. The trade fair, which takes place every November and is co-located to MEDICA in Dusseldorf, has been steadily growing over the past years and shows that medical technology remains a rapidly growing market.

In 2016, the joint pavilion by the IVAM Microtechnology Network, the Product Market “High-tech for Medical Devices”, will be located in Hall 8a again and will...

Im Focus: Ultra-thin ferroelectric material for next-generation electronics

'Ferroelectric' materials can switch between different states of electrical polarization in response to an external electric field. This flexibility means they show promise for many applications, for example in electronic devices and computer memory. Current ferroelectric materials are highly valued for their thermal and chemical stability and rapid electro-mechanical responses, but creating a material that is scalable down to the tiny sizes needed for technologies like silicon-based semiconductors (Si-based CMOS) has proven challenging.

Now, Hiroshi Funakubo and co-workers at the Tokyo Institute of Technology, in collaboration with researchers across Japan, have conducted experiments to...

All Focus news of the innovation-report >>>



Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

Agricultural Trade Developments and Potentials in Central Asia and the South Caucasus

14.10.2016 | Event News

World Health Summit – Day Three: A Call to Action

12.10.2016 | Event News

Latest News

Resolving the mystery of preeclampsia

21.10.2016 | Health and Medicine

Stanford researchers create new special-purpose computer that may someday save us billions

21.10.2016 | Information Technology

From ancient fossils to future cars

21.10.2016 | Materials Sciences

More VideoLinks >>>